Focused On-demand Library for E3 ubiquitin-protein ligase TRIM31

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Tripartite motif-containing protein 31

Alternative UPACC:

Q9BZY9; A6NLX6; A9R9Q4; Q53H52; Q5RI37; Q5SRJ7; Q5SRJ8; Q5SS28; Q96AK4; Q96AP8; Q99579; Q9BZY8


E3 ubiquitin-protein ligase TRIM31, also known as Tripartite motif-containing protein 31, plays a pivotal role in the immune response to viral infections. It regulates antiviral defense by mediating 'Lys-63'-linked ubiquitination of MAVS, enhancing MAVS polymerization on mitochondria. Additionally, TRIM31 acts as a negative regulator of the NLRP3 inflammasome through 'Lys-48'-linked ubiquitination, leading to NLRP3 degradation.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase TRIM31 could open doors to potential therapeutic strategies. Its involvement in regulating antiviral immune responses and inflammation highlights its potential as a target for developing treatments for viral infections and inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.